Comparing PD-L1 with PD-1 antibodies combined with lenvatinib and hepatic arterial infusion chemotherapy for unresectable hepatocellular carcinoma
BackgroundA combination of hepatic arterial infusion chemotherapy (HAIC), lenvatinib, and immune checkpoint inhibitors (ICIs) yields a high tumor response rate and survival benefit in unresectable hepatocellular carcinoma (uHCC). However, the selection criteria for different ICIs remain unclear. Thi...
Saved in:
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2024-10-01
|
| Series: | Frontiers in Immunology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fimmu.2024.1491857/full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850210289474076672 |
|---|---|
| author | Shaohua Li Shaohua Li Jie Mei Jie Mei Rongce Zhao Rongce Zhao Jing Zhou Jing Zhou Qiaoxuan Wang Qiaoxuan Wang Lianghe Lu Lianghe Lu Jibin Li Jibin Li Lie Zheng Lie Zheng Wei Wei Wei Wei Rongping Guo Rongping Guo |
| author_facet | Shaohua Li Shaohua Li Jie Mei Jie Mei Rongce Zhao Rongce Zhao Jing Zhou Jing Zhou Qiaoxuan Wang Qiaoxuan Wang Lianghe Lu Lianghe Lu Jibin Li Jibin Li Lie Zheng Lie Zheng Wei Wei Wei Wei Rongping Guo Rongping Guo |
| author_sort | Shaohua Li |
| collection | DOAJ |
| description | BackgroundA combination of hepatic arterial infusion chemotherapy (HAIC), lenvatinib, and immune checkpoint inhibitors (ICIs) yields a high tumor response rate and survival benefit in unresectable hepatocellular carcinoma (uHCC). However, the selection criteria for different ICIs remain unclear. This study aims to compare the efficacy and safety of PD-1/PD-L1 antibodies combined with HAIC and lenvatinib.MethodsThis retrospective study included 184 patients with uHCC treated with HAIC+lenvatinib+PD-1/PD-L1 antibody from June 2019 to January 2022. We utilized propensity score matching (PSM) to select and match 60 patients treated with HAIC + durvalumab + lenvatinib (HDL) against 60 patients treated with HAIC + PD-1 antibodies + lenvatinib (HPL) to compare the efficacy and safety profiles of these two groups.ResultsAfter PSM, the baseline characteristics were well-balanced between the HDL and HPL groups. The overall survival (p = 0.293) and progression-free survival (p = 0.146) showed no significant difference. The objective response rate (ORR) was higher in the HDL group compared to the HPL group according to modified RECIST (74.1% vs. 53.6%, p = 0.022) and RECIST 1.1 (60.3% vs. 41.1%, p = 0.040), respectively. The incidence of grade 3 or 4 adverse events (AEs) was 10.0% and 18.3% (p = 0.191) in the HDL and HPL groups, respectively.ConclusionsPD-L1 antibody appears to be a preferable companion in the combination therapy of HAIC + ICIs + lenvatinib compared to PD-1 antibody, showing higher ORR and relatively lower incidence of severe AEs. Further prospective studies involving a larger patient population are warranted. |
| format | Article |
| id | doaj-art-5cb8f662cec44405bc4bc6946486ad9c |
| institution | OA Journals |
| issn | 1664-3224 |
| language | English |
| publishDate | 2024-10-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Immunology |
| spelling | doaj-art-5cb8f662cec44405bc4bc6946486ad9c2025-08-20T02:09:48ZengFrontiers Media S.A.Frontiers in Immunology1664-32242024-10-011510.3389/fimmu.2024.14918571491857Comparing PD-L1 with PD-1 antibodies combined with lenvatinib and hepatic arterial infusion chemotherapy for unresectable hepatocellular carcinomaShaohua Li0Shaohua Li1Jie Mei2Jie Mei3Rongce Zhao4Rongce Zhao5Jing Zhou6Jing Zhou7Qiaoxuan Wang8Qiaoxuan Wang9Lianghe Lu10Lianghe Lu11Jibin Li12Jibin Li13Lie Zheng14Lie Zheng15Wei Wei16Wei Wei17Rongping Guo18Rongping Guo19Department of Liver Surgery, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, ChinaState Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Collaborative Innovation Center for Cancer Medicine, Guangzhou, Guangdong, ChinaDepartment of Liver Surgery, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, ChinaState Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Collaborative Innovation Center for Cancer Medicine, Guangzhou, Guangdong, ChinaDepartment of Liver Surgery, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, ChinaState Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Collaborative Innovation Center for Cancer Medicine, Guangzhou, Guangdong, ChinaState Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Collaborative Innovation Center for Cancer Medicine, Guangzhou, Guangdong, ChinaDepartment of Pathology, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, ChinaState Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Collaborative Innovation Center for Cancer Medicine, Guangzhou, Guangdong, ChinaDepartment of Radiation Oncology, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, ChinaDepartment of Liver Surgery, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, ChinaState Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Collaborative Innovation Center for Cancer Medicine, Guangzhou, Guangdong, ChinaState Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Collaborative Innovation Center for Cancer Medicine, Guangzhou, Guangdong, ChinaDepartment of Clinical Research Methodology, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, ChinaState Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Collaborative Innovation Center for Cancer Medicine, Guangzhou, Guangdong, ChinaDepartment of Radiology, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, ChinaDepartment of Liver Surgery, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, ChinaState Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Collaborative Innovation Center for Cancer Medicine, Guangzhou, Guangdong, ChinaDepartment of Liver Surgery, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, ChinaState Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Collaborative Innovation Center for Cancer Medicine, Guangzhou, Guangdong, ChinaBackgroundA combination of hepatic arterial infusion chemotherapy (HAIC), lenvatinib, and immune checkpoint inhibitors (ICIs) yields a high tumor response rate and survival benefit in unresectable hepatocellular carcinoma (uHCC). However, the selection criteria for different ICIs remain unclear. This study aims to compare the efficacy and safety of PD-1/PD-L1 antibodies combined with HAIC and lenvatinib.MethodsThis retrospective study included 184 patients with uHCC treated with HAIC+lenvatinib+PD-1/PD-L1 antibody from June 2019 to January 2022. We utilized propensity score matching (PSM) to select and match 60 patients treated with HAIC + durvalumab + lenvatinib (HDL) against 60 patients treated with HAIC + PD-1 antibodies + lenvatinib (HPL) to compare the efficacy and safety profiles of these two groups.ResultsAfter PSM, the baseline characteristics were well-balanced between the HDL and HPL groups. The overall survival (p = 0.293) and progression-free survival (p = 0.146) showed no significant difference. The objective response rate (ORR) was higher in the HDL group compared to the HPL group according to modified RECIST (74.1% vs. 53.6%, p = 0.022) and RECIST 1.1 (60.3% vs. 41.1%, p = 0.040), respectively. The incidence of grade 3 or 4 adverse events (AEs) was 10.0% and 18.3% (p = 0.191) in the HDL and HPL groups, respectively.ConclusionsPD-L1 antibody appears to be a preferable companion in the combination therapy of HAIC + ICIs + lenvatinib compared to PD-1 antibody, showing higher ORR and relatively lower incidence of severe AEs. Further prospective studies involving a larger patient population are warranted.https://www.frontiersin.org/articles/10.3389/fimmu.2024.1491857/fullhepatocellular carcinomaPD-1/PD-L1 antibodieshepatic arterial infusion chemotherapylenvatinibdurvalumabcombination therapy |
| spellingShingle | Shaohua Li Shaohua Li Jie Mei Jie Mei Rongce Zhao Rongce Zhao Jing Zhou Jing Zhou Qiaoxuan Wang Qiaoxuan Wang Lianghe Lu Lianghe Lu Jibin Li Jibin Li Lie Zheng Lie Zheng Wei Wei Wei Wei Rongping Guo Rongping Guo Comparing PD-L1 with PD-1 antibodies combined with lenvatinib and hepatic arterial infusion chemotherapy for unresectable hepatocellular carcinoma Frontiers in Immunology hepatocellular carcinoma PD-1/PD-L1 antibodies hepatic arterial infusion chemotherapy lenvatinib durvalumab combination therapy |
| title | Comparing PD-L1 with PD-1 antibodies combined with lenvatinib and hepatic arterial infusion chemotherapy for unresectable hepatocellular carcinoma |
| title_full | Comparing PD-L1 with PD-1 antibodies combined with lenvatinib and hepatic arterial infusion chemotherapy for unresectable hepatocellular carcinoma |
| title_fullStr | Comparing PD-L1 with PD-1 antibodies combined with lenvatinib and hepatic arterial infusion chemotherapy for unresectable hepatocellular carcinoma |
| title_full_unstemmed | Comparing PD-L1 with PD-1 antibodies combined with lenvatinib and hepatic arterial infusion chemotherapy for unresectable hepatocellular carcinoma |
| title_short | Comparing PD-L1 with PD-1 antibodies combined with lenvatinib and hepatic arterial infusion chemotherapy for unresectable hepatocellular carcinoma |
| title_sort | comparing pd l1 with pd 1 antibodies combined with lenvatinib and hepatic arterial infusion chemotherapy for unresectable hepatocellular carcinoma |
| topic | hepatocellular carcinoma PD-1/PD-L1 antibodies hepatic arterial infusion chemotherapy lenvatinib durvalumab combination therapy |
| url | https://www.frontiersin.org/articles/10.3389/fimmu.2024.1491857/full |
| work_keys_str_mv | AT shaohuali comparingpdl1withpd1antibodiescombinedwithlenvatinibandhepaticarterialinfusionchemotherapyforunresectablehepatocellularcarcinoma AT shaohuali comparingpdl1withpd1antibodiescombinedwithlenvatinibandhepaticarterialinfusionchemotherapyforunresectablehepatocellularcarcinoma AT jiemei comparingpdl1withpd1antibodiescombinedwithlenvatinibandhepaticarterialinfusionchemotherapyforunresectablehepatocellularcarcinoma AT jiemei comparingpdl1withpd1antibodiescombinedwithlenvatinibandhepaticarterialinfusionchemotherapyforunresectablehepatocellularcarcinoma AT rongcezhao comparingpdl1withpd1antibodiescombinedwithlenvatinibandhepaticarterialinfusionchemotherapyforunresectablehepatocellularcarcinoma AT rongcezhao comparingpdl1withpd1antibodiescombinedwithlenvatinibandhepaticarterialinfusionchemotherapyforunresectablehepatocellularcarcinoma AT jingzhou comparingpdl1withpd1antibodiescombinedwithlenvatinibandhepaticarterialinfusionchemotherapyforunresectablehepatocellularcarcinoma AT jingzhou comparingpdl1withpd1antibodiescombinedwithlenvatinibandhepaticarterialinfusionchemotherapyforunresectablehepatocellularcarcinoma AT qiaoxuanwang comparingpdl1withpd1antibodiescombinedwithlenvatinibandhepaticarterialinfusionchemotherapyforunresectablehepatocellularcarcinoma AT qiaoxuanwang comparingpdl1withpd1antibodiescombinedwithlenvatinibandhepaticarterialinfusionchemotherapyforunresectablehepatocellularcarcinoma AT lianghelu comparingpdl1withpd1antibodiescombinedwithlenvatinibandhepaticarterialinfusionchemotherapyforunresectablehepatocellularcarcinoma AT lianghelu comparingpdl1withpd1antibodiescombinedwithlenvatinibandhepaticarterialinfusionchemotherapyforunresectablehepatocellularcarcinoma AT jibinli comparingpdl1withpd1antibodiescombinedwithlenvatinibandhepaticarterialinfusionchemotherapyforunresectablehepatocellularcarcinoma AT jibinli comparingpdl1withpd1antibodiescombinedwithlenvatinibandhepaticarterialinfusionchemotherapyforunresectablehepatocellularcarcinoma AT liezheng comparingpdl1withpd1antibodiescombinedwithlenvatinibandhepaticarterialinfusionchemotherapyforunresectablehepatocellularcarcinoma AT liezheng comparingpdl1withpd1antibodiescombinedwithlenvatinibandhepaticarterialinfusionchemotherapyforunresectablehepatocellularcarcinoma AT weiwei comparingpdl1withpd1antibodiescombinedwithlenvatinibandhepaticarterialinfusionchemotherapyforunresectablehepatocellularcarcinoma AT weiwei comparingpdl1withpd1antibodiescombinedwithlenvatinibandhepaticarterialinfusionchemotherapyforunresectablehepatocellularcarcinoma AT rongpingguo comparingpdl1withpd1antibodiescombinedwithlenvatinibandhepaticarterialinfusionchemotherapyforunresectablehepatocellularcarcinoma AT rongpingguo comparingpdl1withpd1antibodiescombinedwithlenvatinibandhepaticarterialinfusionchemotherapyforunresectablehepatocellularcarcinoma |